413 results about "Central nerve system" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The present invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents to deliver pharmaceutical compounds into or through cells during receptor-mediated endocytosis and / or transendocytosis processes. As transferrin receptors are also present in the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase delivery of pharmaceutical compounds to the central nervous system.

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The present disclosure provides a method of producing a non-human mammalian animal model comprising human neural tissue, the method comprising introducing a first human neural organoid into a central nervous system location of a newborn non-human mammal; and allowing the newborn non-human mammal to mature to produce the non-human mammalian animal model comprising human neural tissue. The present disclosure provides a method of modeling a neuropsychiatric disorder. The present disclosure also provides a method of determining the effectiveness of a candidate agent on a neuropsychiatric disorder. The present disclosure provides a method for altering the behavior of a mammal. Also provided are non-human mammalian animal models comprising human neural tissue.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The invention discloses a tea leaf theanine composition for protecting a central nervous system as well as a preparation method and application thereof, relates to the field of common foods and health-care foods, and aims to solve the problems that most of existing central nervous protection products are single components or are simply compounded, the synergistic effect is weak and the bioavailability is low. The preparation method comprises the following steps: S1, mixing the tea leaf theanine, the emblic leafflower fruit powder, the ginkgo leaf extract, the wolfberry fruit powder and other raw materials according to a specific ratio, and performing high-temperature sterilization and cooling to obtain a fermentation substrate; s2, inoculating a composite activation microbial inoculum composed of plant lactobacillus, lactobacillus acidophilus and lactobacillus reuteri, and carrying out constant-temperature anaerobic fermentation; and S3, freezing and centrifuging at 4 DEG C, concentrating with an RO membrane, and freezing and drying to obtain the composition. The viable count of the complex microbial inoculant reaches 2.0 * 10 < 9 >-3.0 * 10 < 9 > CFU / mL, and the strain ratio and the fermentation process are optimized. The composition has a synergistic effect of multiple components, can efficiently protect nervous centralis, and is suitable for preparing related common food, health food or functional food.

The invention discloses a nutritional composition for promoting central nervous system development and application. The invention provides a nutritional composition for promoting the development of a central nervous system. The nutritional composition comprises the following necessary components: a breast milk oligosaccharide component and a casein phosphopeptide component, moreover, in the composition, the mass ratio of the breast milk oligosaccharide component to the casein phosphopeptide component is (1-100): (500-1). According to the invention, the breast milk oligosaccharide component and the casein phosphopeptides are matched to prepare the nutritional composition, and the nutritional composition can significantly promote nerve development such as neuronal maturation, synaptic generation and myelin sheath formation.

The present invention provides CXCR4 inhibitors of formula (I) and pharmaceutically acceptable salts thereof, as well as methods of using them in the treatment of neurological and CNS diseases, disorders, and conditions. The provided compounds are inhibitors of CXCR4 and are therefore useful for treating one or more disorders associated with CXCR4 activity. Thus, in certain embodiments, the present invention provides a method for treating a CXCR4-mediated disorder, comprising administering to a patient in need thereof a CXCR4 inhibitor described herein, such as a compound of formula I or a pharmaceutically acceptable salt thereof. Certain embodiments of the present invention are directed to the use of CXCR4 inhibitors that, when administered to a subject, cross the blood-brain barrier (BBB) ​​and enter the brain and central nervous system (CNS). JPEG2026502774000083.jpg3135

The invention relates to the technical field of medicines, in particular to application of a mesenchymal stem cell exosome in preparation of a thermoplegia neuroprotective agent. It is found through experiments that MSC-Exos can remarkably promote polarization conversion of microglial cells from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and therefore damage, caused by heat stroke, to a central nervous system is relieved.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

Systems and methods for radiofrequency neurotomy. Systems include needles with deployable filaments capable of producing lesions at target volumes, which may include a target nerve. Ablation of at least a portion of the target nerve may inhibit the ability of the nerve to transmit signals, such as pain signals, to the central nervous system. The lesion may facilitate procedures by directing energy towards the target nerve and away from collateral structures. Example anatomical structures include lumbar, thoracic, and cervical medial branch nerves and rami and the sacroiliac joint.

A conjugate comprising a ligand that targets a folate receptor linked to an acrolein scavenger drug; a composition comprising same; a method of using the conjugate or the composition to scavenge acrolein, alone or in further combination with other reactive aldehyde species, in a subject with neurotrauma; and a method of delivering an acrolein scavenger or an imaging agent to the central nervous system (CNS) of a patient with inflammation in the CNS.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a huntingtin (HTT) gene. The HTT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an HTT gene. The HTT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more HTT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described HTT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of HTT gene expression and a reduction in HTT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Huntington's Disease.

This application relates to nucleic acid regulatory elements (NAREs) that can enhance gene expression in the central nervous system. This application further relates to methods utilizing NAREs and uses of NAREs. Expression cassettes and vectors containing NAREs are also disclosed. These are particularly useful for applications using gene therapy.

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a MutS Homolog 3 (MSH3) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having Huntington's Disease.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention belongs to the field of pathologies affecting the central nervous system: in particular, severe cerebral pathologies, more particularly those restricted by the presence of the blood-brain barrier (BBB): gliomas, cerebral metastases, neurodegenerative diseases (e.g. Alzheimer's, Parkinson's or ALS), genetic diseases (Huntington's, myopathies, Leigh syndrome, Rett syndrome), but also to the field of cancers, musculoskeletal and immunological disorders, vascular diseases (thrombus) in numerous organs (e.g. liver, kidney or muscle) and in combination with numerous therapeutic approaches (e.g. chemotherapy, immunotherapy, targeted therapy or gene therapy). The invention relates to a microbubble comprising a fluorinated polymer or copolymer and a fluorinated gas, to the use thereof and also to the polymer or copolymer intermediate compounds.

The present disclosure relates to compounds according to Formula I or a pharmaceutically acceptable salt and / or solvate thereof, wherein X 1 is H, F, or CI; R 1 is H, alkyl, or cycloalkyl; R 2 is H, alkyl, or cycloalkyl; R 3 is H, halo, alkyl, cycloalkyl, heterocyclyl, heteroaryl, or N(R 4 )(R 5 ); and one of R 4 and R 5 is H, alkyl, cycloalkyl, heterocyclyl, or heteroaryl, and the remaining one of R 1 and R 2 is H or alkyl, or R 4 and R 5 together with the nitrogen atom to which they are bound are heterocyclyl or heteroaryl. Furthermore, the present disclosure demonstrates that the compounds of the present disclosure penetrate the central nervous system, thereby allowing for the treatment of central nervous system cancers.

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

This invention relates generally to compositions and methods for modulating cellular activities using multi-characteristic opsin (MCO). Further, the invention provides methods for treating ailments related to activity of the dorsal root ganglia (DRG), anterior cingulate cortex (ACC) or spinal cord including neuropathic pain. Specific embodiments include methods of modulating inhibitory pathways to inhibit chronic neuropathic pain. The methods can use a light sensitive optogenetic actuator with inhibitory neuron specificity. Embodiments also include an optogenetic pain modulator device that can regulate the frequency and intensity of optogenetic stimulation.

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

How to treat injuries or conditions associated with CNS edema [Solution] This technology relates to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the method includes reducing late neurological exacerbations or preventing death, reducing midline deviation of the brain, reducing the degree of functional impairment in subjects, neutralizing blood glucose levels in subjects receiving SUR1-TRPM4 channel inhibitors, preventing cerebral swelling, treating injuries or conditions associated with CNS edema while monitoring liver enzyme activity, or treating injuries or conditions associated with CNS edema while monitoring cardiac activity.

This invention provides a near-infrared therapy device for improving Alzheimer's disease, characterized by comprising: a frequency-modulated drive circuit 1, a near-infrared LD light source 2, an optical fiber coupler 3, a light source power monitoring photodetector (PD) 4, an optical power monitoring circuit 5, an optical fiber beam splitter 6, an MPO optical fiber cable 7, and an optical transmitter 8. The optical transmitter includes an optical transmitter housing 8-1, a fiber-end hemispherical emitting microlens 8-2, and a beam-shaping coupling lens 8-3. This invention can be used to regulate the metabolism and cellular function of meningeal lymphatic endothelial mitochondrial cells, promote meningeal lymphatic transport in the central nervous system, thereby alleviating the pathological symptoms of Alzheimer's patients and enhancing their cognitive function. The device has a simple and compact structure, is easy to plug and unplug, has low optical signal loss, and high coupling efficiency. It can be widely used in novel non-invasive optical brain-computer interface devices and belongs to the field of fiber optic sensing technology.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

1. Name of the product in this design: Electromyography Evoked Potential Instrument. 2. Purpose of this design: To determine the functional status and suspected lesions of the peripheral neuromuscular system and central nervous system, detect subclinical lesions, and accurately locate lesions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The bottom surface of this product is a part that is not easily seen or cannot be seen during use, so the bottom view is omitted.

The application discloses a polypeptide GRN-E and application thereof in preparation of a medicine or preparation for perimenopausal emotional disorder. It is found for the first time that a GRN-E fragment (a C-terminal domain of PGRN, an amino acid sequence is SEQ ID NO. 1 in a sequence listing) can pass through a blood-brain barrier and has a unique effect in relieving perimenopausal anxiety and depression. As a key functional fragment, the GRN-E has a more concentrated effect on a central nervous system and can effectively avoid off-target effects of a full-length protein. The polypeptide GRN-E of the application can be applied to preparation of a medicine or preparation for perimenopausal emotional disorder as an innovative treatment target and a novel biological preparation and has a high clinical conversion value.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis. Using human neuroblastoma cells (SH-SY5Y) as target cells, this invention utilizes activators from a library of ubiquitinated compounds to target and activate key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally discovered that NEDD8 activator (NAE) has the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.